Groundbreaking technology from PeraHealth that monitors patient health and flags up anomalies has been given the green light by the Food and Drug Administration (FDA).
The launch of Celgene’s multiple sclerosis drug, ozanimod, will be delayed after the company failed to submit key information in its application to the Food and Drug Administration (FDA).
